Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125

Biochemical Pharmacology

Volumn 84, Issue 5, 2012, Pages 598-611

  Caporali, Simona ^a   Alvino, Ester ^b   Levati, Lauretta ^a   Esposito, Alessia I ^c   Ciomei, Marina ^d   Brasca, Maria G ^d   Del Bufalo, Donatella ^e   Desideri, Marianna ^e   Bonmassar, Enzo ^b,f   Pfeffer, Ulrich ^c   D'Atri, Stefania ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d NERVIANO MEDICAL SCIENCES   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Gene expression profile; Melanoma; PHA 848125; Proliferation; PTTG1

Indexed keywords

AURORA A KINASE; AURORA B KINASE; BACULOVIRAL IAP REPEAT CONTAINING 5 PROTEIN; CELL DIVISION CONTROL PROTEIN 25A; DEP DOMAIN CONTAINING 6 PROTEIN; DNA DAMAGE INDUCIBLE TRANSCRIPT 4 PROTEIN; MILCICLIB; POLO LIKE KINASE 1; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 4 RECEPTOR; PROTEIN; PROTEIN P53; SECURIN; SESTRIN 2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTO ONCOGENE; SENESCENCE; UPREGULATION;

CELL DIVISION; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; DOWN-REGULATION; GENE REGULATORY NETWORKS; HUMANS; MELANOMA; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENES; PYRAZOLES; QUINAZOLINES; RNA, SMALL INTERFERING;

EID: 84864416956     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.06.004     Document Type: Article

References (66)

1. M. Berwick, E. Erdei, and J. Hay Melanoma epidemiology and public health Dermatol Clin 27 2009 205 214 viii
2. H.A. Tawbi, and J.M. Kirkwood Management of metastatic melanoma Semin Oncol 34 2007 532 545
3. C. Garbe, T.K. Eigentler, U. Keilholz, A. Hauschild, and J.M. Kirkwood Systematic review of medical treatment in melanoma: current status and future prospects Oncologist 16 2011 5 24
4. I. Quirt, S. Verma, T. Petrella, K. Bak, and M. Charette Temozolomide for the treatment of metastatic melanoma: a systematic review Oncologist 12 2007 1114 1123
5. M.J. Payne, S.E. Pratap, and M.R. Middleton Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling Crit Rev Oncol Hematol 53 2005 241 252
6. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, and J.B. Haanen Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
7. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, and J. Larkin Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
8. L.A. Fecher, S.D. Cummings, M.J. Keefe, and R.M. Alani Toward a molecular classification of melanoma J Clin Oncol 25 2007 1606 1620
9. N. Ibrahim, and F.G. Haluska Molecular pathogenesis of cutaneous melanocytic neoplasms Annu Rev Pathol 4 2009 551 579
10. S. Lapenna, and A. Giordano Cell cycle kinases as therapeutic targets for cancer Nat Rev Drug Discov 8 2009 547 566
11. M. Malumbres, and M. Barbacid Cell cycle, CDKs and cancer: a changing paradigm Nat Rev Cancer 9 2009 153 166
12. F. Rizzolio, T. Tuccinardi, I. Caligiuri, C. Lucchetti, and A. Giordano CDK inhibitors: from the bench to clinical trials Curr Drug Targets 11 2010 279 290
13. M. Malumbres, P. Pevarello, M. Barbacid, and J.R. Bischoff CDK inhibitors in cancer therapy: what is next Trends Pharmacol Sci 29 2008 16 21
14. C. Albanese, R. Alzani, N. Amboldi, N. Avanzi, D. Ballinari, and M.G. Brasca Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy Mol Cancer Ther 9 2010 2243 2254
15. A. Degrassi, M. Russo, C. Nanni, V. Patton, R. Alzani, and A.M. Giusti Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging Mol Cancer Ther 9 2010 673 681
16. M.G. Brasca, N. Amboldi, D. Ballinari, A. Cameron, E. Casale, and G. Cervi Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl) phenyl]amino}-4,5-dihydr o-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor J Med Chem 52 2009 5152 5163
17. R. Tibes, A. Jimeno, D.D. Von Hoff, R. Walker, M.A. Pacciarini, and A. Scaburri Phase I dose escalation study of the oral multi-cdk inhibitor PHA-848125 J Clin Oncol 26 May 20 Suppl. 2008 abstr 3531
18. S. Caporali, E. Alvino, G. Starace, M. Ciomei, M.G. Brasca, and L. Levati The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound Pharmacol Res 61 2010 437 448
19. 6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea and cisplatin J Pharmacol Exp Ther 304 2003 661 668
20. S.H. Golub, D.C. Hanson, H.L. Sulit, D.L. Morton, M.A. Pellegrino, and S. Ferrone Comparison of histocompatibility antigens on cultured human tumor cells and fibroblasts by quantitative antibody absorption and sensitivity to cell-mediated cytotoxicity J Natl Cancer Inst 56 1976 167 170
21. S. Bondanza, R. Maurelli, P. Paterna, E. Migliore, F.D. Giacomo, and G. Primavera Keratinocyte cultures from involved skin in vitiligo patients show an impaired in vitro behaviour Pigment Cell Res 20 2007 288 300
22. R.A. Irizarry, B.M. Bolstad, F. Collin, L.M. Cope, B. Hobbs, and T.P. Speed Summaries of Affymetrix GeneChip probe level data Nucleic Acids Res 31 2003 e15
23. R.C. Gentleman, V.J. Carey, D.M. Bates, B. Bolstad, M. Dettling, and S. Dudoit Bioconductor: open software development for computational biology and bioinformatics Genome Biol 5 2004 R80
24. V.G. Tusher, R. Tibshirani, and G. Chu Significance analysis of microarrays applied to the ionizing radiation response Proc Natl Acad Sci USA 98 2001 5116 5121
25. G. Dennis Jr., B.T. Sherman, D.A. Hosack, J. Yang, W. Gao, and H.C. Lane DAVID: Database for Annotation, Visualization, and Integrated Discovery Genome Biol 4 2003 P3
26. C. Huttenhower, E.M. Haley, M.A. Hibbs, V. Dumeaux, D.R. Barrett, and H.A. Coller Exploring the human genome with functional maps Genome Res 19 2009 1093 1106
27. E. Howe, K. Holton, S. Nair, D. Slauch, R. Sinha, and J. Quackembush MeV: Multi Experiment Viewer M.F. Ochs, J.T. Casagrande, R.V. Davuluri, Biomedical informatics for cancer research 2010 Springer New York p. 267-77
28. H. Kiyokawa, and D. Ray In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets Anticancer Agents Med Chem 8 2008 832 836
29. S.K. Panguluri, C. Yeakel, and S.S. Kakar PTTG: an important target gene for ovarian cancer therapy J Ovarian Res 1 2008 6
30. G. Vlotides, T. Eigler, and S. Melmed Pituitary tumor-transforming gene: physiology and implications for tumorigenesis Endocr Rev 28 2007 165 186
31. L.W. Ellisen Growth control under stress: mTOR regulation through the REDD1-TSC pathway Cell Cycle 4 2005 1500 1502
32. B. Lankat-Buttgereit, and R. Goke The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation Biol Cell 101 2009 309 317
33. A.V. Budanov Stress-responsive sestrins link p53 with redox regulation and mammalian target of rapamycin signaling Antioxid Redox Signal 15 2011 1679 1690
34. T.R. Peterson, M. Laplante, C.C. Thoreen, Y. Sancak, S.A. Kang, and W.M. Kuehl DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival Cell 137 2009 873 886
35. R.J. Kelly, A. Lopez-Chavez, D. Citrin, J.E. Janik, and J.C. Morris Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin Mol Cancer 10 2011 35
36. D.C. Altieri Survivin, cancer networks and pathway-directed drug discovery Nat Rev Cancer 8 2008 61 70
37. J.A. Bernal, R. Luna, A. Espina, I. Lazaro, F. Ramos-Morales, and F. Romero Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis Nat Genet 32 2002 306 311
38. V. Winnepenninckx, M. Debiec-Rychter, J.A. Belien, P. Fiten, S. Michiels, and V. Lazar Expression and possible role of hPTTG1/securin in cutaneous malignant melanoma Mod Pathol 19 2006 1170 1180
39. Y. Tong, W. Zhao, C. Zhou, K. Wawrowsky, and S. Melmed PTTG1 attenuates drug-induced cellular senescence PLoS One 6 2011 e23754
40. P.S. Kho, Z. Wang, L. Zhuang, Y. Li, J.L. Chew, and H.H. Ng p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis J Biol Chem 279 2004 21183 21192
41. Y. Zhou, K.R. Mehta, A.P. Choi, S. Scolavino, and X. Zhang DNA damage-induced inhibition of securin expression is mediated by p53 J Biol Chem 278 2003 462 470
42. S.R. Whittaker, R.H. Te Poele, F. Chan, S. Linardopoulos, M.I. Walton, and M.D. Garrett The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis Cell Cycle 6 2007 3114 3131
43. D.L. Burkhart, and J. Sage Cellular mechanisms of tumour suppression by the retinoblastoma gene Nat Rev Cancer 8 2008 671 682
44. H.Z. Chen, S.Y. Tsai, and G. Leone Emerging roles of E2Fs in cancer: an exit from cell cycle control Nat Rev Cancer 9 2009 785 797
45. S. Ishida, E. Huang, H. Zuzan, R. Spang, G. Leone, and M. West Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis Mol Cell Biol 21 2001 4684 4699
46. S. Polager, Y. Kalma, E. Berkovich, and D. Ginsberg E2Fs up-regulate expression of genes involved in DNA replication, DNA repair and mitosis Oncogene 21 2002 437 446
47. G. Locatelli, R. Bosotti, M. Ciomei, M.G. Brasca, R. Calogero, and C. Mercurio Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study Mol Cancer Ther 9 2010 1265 1273
48. S.J. Ho Sui, J.R. Mortimer, D.J. Arenillas, J. Brumm, C.J. Walsh, and B.P. Kennedy oPOSSUM: identification of over-represented transcription factor binding sites in co-expressed genes Nucleic Acids Res 33 2005 3154 3164
49. Q. Deng, Q. Wang, W.Y. Zong, D.L. Zheng, Y.X. Wen, and K.S. Wang E2F8 contributes to human hepatocellular carcinoma via regulating cell proliferation Cancer Res 70 2010 782 791
50. R.P. Fisher Secrets of a double agent: CDK7 in cell-cycle control and transcription J Cell Sci 118 2005 5171 5180
51. A. Kauffmann, F. Rosselli, V. Lazar, V. Winnepenninckx, A. Mansuet-Lupo, and P. Dessen High expression of DNA repair pathways is associated with metastasis in melanoma patients Oncogene 27 2008 565 573
52. V. Winnepenninckx, V. Lazar, S. Michiels, P. Dessen, M. Stas, and S.R. Alonso Gene expression profiling of primary cutaneous melanoma and clinical outcome J Natl Cancer Inst 98 2006 472 482
53. V. Zuckermann, K. Wolniec, R.V. Sionov, S. Haupt, and Y. Haupt Tumour suppression by p53: the importance of apoptosis and cellular senescence J Pathol 219 2009 3 15
54. D.S. Kim, J.A. Franklyn, V.E. Smith, A.L. Stratford, H.N. Pemberton, and A. Warfield Securin induces genetic instability in colorectal cancer by inhibiting double-stranded DNA repair activity Carcinogenesis 28 2007 749 759
55. F. Romero, A.M. Gil-Bernabe, C. Saez, M.A. Japon, J.A. Pintor-Toro, and M. Tortolero Securin is a target of the UV response pathway in mammalian cells Mol Cell Biol 24 2004 2720 2733
56. Y. Lai, D. Xin, J. Bai, Z. Mao, and Y. Na The important anti-apoptotic role and its regulation mechanism of PTTG1 in UV-induced apoptosis J Biochem Mol Biol 40 2007 966 972
57. A.Y. Olsson, A. Feber, S. Edwards, R. Te Poele, I. Giddings, and S. Merson Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells Oncogene 26 2007 1028 1037
58. C. Zhou, K. Wawrowsky, S. Bannykh, S. Gutman, and S. Melmed E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors Mol Endocrinol 23 2009 2000 2012
59. O. Afonja, D. Juste, S. Das, S. Matsuhashi, and H.H. Samuels Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis Oncogene 23 2004 8135 8145
60. N. Carayol, E. Katsoulidis, A. Sassano, J.K. Altman, B.J. Druker, and L.C. Platanias Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway J Biol Chem 283 2008 8601 8610
61. R.M. Memmott, and P.A. Dennis Akt-dependent and -independent mechanisms of mTOR regulation in cancer Cell Signal 21 2009 656 664
62. M.P. DeYoung, P. Horak, A. Sofer, D. Sgroi, and L.W. Ellisen Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling Genes Dev 22 2008 239 251
63. M. Karbowniczek, C.S. Spittle, T. Morrison, H. Wu, and E.P. Henske mTOR is activated in the majority of malignant melanomas J Invest Dermatol 128 2008 980 987
64. K.R. Molhoek, D.L. Brautigan, and C.L. Slingluff Jr. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin J Transl Med 3 2005 39
65. T. Sinnberg, K. Lasithiotakis, H. Niessner, B. Schittek, K.T. Flaherty, and D. Kulms Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide J Invest Dermatol 129 2009 1500 1515
66. K.G. Lasithiotakis, T.W. Sinnberg, B. Schittek, K.T. Flaherty, D. Kulms, and E. Maczey Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells J Invest Dermatol 128 2008 2013 2023